

# Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD


Canadian Association of Radiologists Journal  
1–12

© The Author(s) 2025



Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/08465371251357447  
journals.sagepub.com/home/caj



Mitchell P. Wilson<sup>1</sup> , Gavin Low<sup>1</sup> , Abdel-Aziz Shaheen<sup>2</sup>, Andreu F. Costa<sup>3</sup> , An Tang<sup>4</sup> , Emily Pang<sup>5</sup>, Silvia Chang<sup>5</sup> , Alexandra Medellin<sup>2</sup> , Jérémy Dana<sup>6</sup> , Noam Millo<sup>7</sup>, Ania Kielar<sup>8</sup> , Li Xin Zhang<sup>4</sup> , Toni Whitaker<sup>1</sup>, Mark Swain<sup>2</sup>, Victoria Leung<sup>1</sup>, Daisy Fung<sup>1</sup> , Casey Hurrell<sup>9</sup> , and Christopher Fung<sup>1</sup> 

## Abstract

The Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) is a multidisciplinary working group composed of radiologists, hepatologists, and family physicians. In this 3-part series, we provide Delphi consensus-based guidance on clinical and imaging findings for patients with known or suspected MASLD (formerly termed nonalcoholic fatty liver disease or NAFLD). Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk-stratification of patients with MASLD, including a patient pathway using serological and imaging investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) programs. In Part 2 of these guidelines, the WG provides 14 recommendations for risk stratifying MASLD patients into low and high risk for advanced hepatic fibrosis ( $F \geq 3$ ) using a combination of serological and imaging investigations. Population screening and risk stratification of MASLD patients using a clinical and serological investigation (FIB-4) followed by imaging pathway is recommended. Clinical, technical, and grading recommendations for point shear wave elastography (pSWE), 2-dimensional SWE (2D-SWE), and MRE are discussed.

## Résumé

Le groupe de travail sur la maladie du foie associée à un dysfonctionnement métabolique (MASLD) de l'Association canadienne des radiologistes (CAR) est un groupe multidisciplinaire composé de radiologistes, d'hépatologues et de médecin de famille. Dans cette série en trois volets, nous présentons des recommandations fondées sur un consensus Delphi et portant sur les constatations cliniques et d'imagerie chez les patients atteints de MASLD ou chez qui l'on soupçonne une MASLD (anciennement désignée sous le nom de stéatose hépatique non alcoolique ou NAFLD). La première partie est consacrée à la détection et à la détermination de la gradation de la stéatose hépatique par imagerie. La deuxième porte sur la stratification du risque chez les personnes atteintes de MASLD, y compris un parcours clinique intégrant des analyses sérologiques et des examens par imagerie. Enfin, la troisième partie traite de la mise en œuvre des recommandations cliniques en matière d'assurance de la qualité pour la détermination du stade de la maladie à l'aide de l'élastographie par onde de cisaillement et de l'élastographie par résonance magnétique. Dans la deuxième partie de ces lignes directrices, le groupe de travail formule 14 recommandations visant à stratifier les patients atteints de MASLD selon leur risque de fibrose hépatique avancée ( $F \geq 3$ ), à l'aide d'un ensemble d'examen sérologiques et d'examen par imagerie. Il est recommandé de procéder au dépistage de masse et à la stratification du risque des patients atteints de MASLD en suivant un algorithme clinique fondé sur une évaluation sérologique (FIB-4), suivie d'examen d'imagerie. Des recommandations cliniques, techniques et de gradation sont formulées à l'égard de l'élastographie ponctuelle par onde de cisaillement, de l'élastographie bidimensionnelle par onde de cisaillement et de l'élastographie par résonance magnétique.

## Keywords

metabolic-associated steatotic liver disease, liver cirrhosis, liver fibrosis, elastography, ultrasonography, magnetic resonance elastography, risk assessment, practice guidelines, biomarkers, noninvasive diagnostic techniques

## Background

The Canadian Association of Radiologists (CAR) metabolic dysfunction-associated steatotic liver disease (MASLD) Working Group (WG) was established in 2024 through the Canadian Society of Abdominal Radiologists (CSAR) and is composed of radiologists, hepatologists, family physicians, a radiology trainee, and an ultrasound technologist from across Canada. The WG was convened to provide unified practice recommendations in patients with MASLD. The WG developed a 3-part comprehensive set of guidance recommendations. Part 1 focuses on the detection and grading of hepatic steatosis on imaging; Part 2 on risk stratification of patients with MASLD, including a patient pathway using serological and imaging investigations; and Part 3 on the implementation of practice recommendations for quality assurance using shear wave elastography (SWE) and magnetic resonance elastography (MRE) programs. Background details and methodology for the CAR MASLD WG in addition to a list of 17 guidance statements for imaging detection and multi-modality grading of hepatic steatosis are described in Part 1.<sup>1</sup> Part 2 of this series offers recommendations for population level risk stratification of patients with MASLD.

Several non-invasive measures for screening and risk stratification of the MASLD population have been developed including serological (blood-based) and imaging (imaging-based) investigations. The Fibrosis-4 Index (FIB-4) has become the most widely accepted blood-based investigation calculated from patient age, aspartate aminotransferase level (AST), alanine aminotransferase level (ALT), and platelet count. Imaging-based investigations of liver stiffness, an indirect measure of liver fibrosis, include vibration-controlled transient elastography (TE) (FibroScan; Echosens), shear wave elastography (SWE), and MR elastography (MRE). Shear wave elastography is further subdivided into point SWE (pSWE) and 2 dimensional SWE (2D-SWE). Transient elastography is the most widely studied tool having been used in liver specialist clinics since the mid-2000s and uses an external mechanical vibration to generate a quantitative evaluation of liver stiffness without structural details of the liver. By contrast, SWE uses a focused short-duration acoustic impulse which enables a single measurement (pSWE) or an image (2D-SWE). Shear wave elastography software is typically integrated into ultrasound machines and available as an

add-on vendor-specific proprietary technology which can be performed in conjunction with B-mode and color Doppler imaging. Finally, MRE measures shear stiffness by using an external driver to produce and transmit mechanical vibrations and phase-contrast sequences with motion-encoding gradients to image shear-wave propagation. Unlike ultrasound-based elastography techniques, MRE hardware and software are standardized across major MRI vendors.

Recent North American and European guidelines have offered recommendations for risk-stratifying patients with MASLD using non-invasive investigations.<sup>2-5</sup> Most society and multi-society clinically-based guidelines have recommended a 2-step blood-based followed by imaging-based recommendation to risk-stratify patients into low versus high-risk for advanced hepatic fibrosis ( $F \geq 3$ ).<sup>2,4</sup> One guideline recommends further risk stratification by disease severity.<sup>3</sup> All guidelines use modality and vendor agnostic thresholds for their recommendations. By contrast, the Society of Radiologists in Ultrasound offers an image-based multi-threshold risk stratification approach using either pSWE or 2D-SWE.<sup>5</sup>

## Part 2: Liver Stiffness Recommendations

A multi-round Delphi methodology using a 5-point Likert scale with consensus threshold established as a score of  $\geq 4.0$  by  $\geq 60\%$  of the WG was used and is explained in further detail in Part 1.<sup>1</sup> Through this process, a list of 14 recommendations for risk stratifying patients with MASLD were developed and are shown in Table 1. The CAR MASLD WG strategy for population screening and risk stratification of MASLD patients is shown in Figure 1.

### Part 2A: Image-Based Liver Stiffness Measurement Indications

**Recommendation 1: The CAR MASLD WG recommends a 2-step blood-based followed by imaging-based, non-invasive investigation for population screening and referral pathways in primary care.**

<sup>1</sup>University of Alberta, Edmonton, AB, Canada

<sup>2</sup>University of Calgary, Calgary, AB, Canada

<sup>3</sup>Dalhousie University, Halifax, NS, Canada

<sup>4</sup>Université de Montréal, Montréal, QC, Canada

<sup>5</sup>University of British Columbia, Vancouver, BC, Canada

<sup>6</sup>McGill University, Montreal, QC, Canada

<sup>7</sup>University of Manitoba, Winnipeg, MB, Canada

<sup>8</sup>University of Toronto, Toronto, ON, Canada

<sup>9</sup>Canadian Association of Radiologists, Ottawa, ON, Canada

#### Corresponding Author:

Mitchell P. Wilson, Department of Radiology and Diagnostic Imaging, University of Alberta, 2B2.41 WMC, 8440-112 Street NW, Edmonton, AB T6G 2B7, Canada.

Email: mitch.wilson@ualberta.ca

**Table 1.** Summary Recommendations for Ultrasound and MR Liver Stiffness Measurements.

Category	Recommendation
Image-based liver stiffness measurement indications.	<ol style="list-style-type: none"> <li>1. The Canadian Association of Radiologists MASLD Guideline Working Group (CAR MASLD WG) supports a 2-step blood-based followed by imaging-based non-invasive investigation for population screening and referral pathways in primary care.</li> <li>2. The CAR MASLD WG supports preferential use of FIB-4 investigation as the blood-based investigation of choice. Recommendations are as follows: <ol style="list-style-type: none"> <li>a. FIB-4 score <math>&lt;1.3</math> = Low risk for advanced liver disease. Repeat FIB-4 examination in 1-3 years.</li> <li>b. FIB-4 score 1.3-2.67 = Indeterminate risk for advanced liver disease. Proceed with imaging-based investigation for liver stiffness measurement.</li> <li>c. FIB-4 score <math>&gt;2.67</math> = High risk for advanced liver disease. Refer to a liver specialist.</li> </ol> </li> </ol>
Comparative utility of image-based modalities for liver stiffness measurement.	<ol style="list-style-type: none"> <li>3. For imaging-based investigations, transient elastography (TE), point shear wave elastography (pSWE), 2D shear wave elastography (2D-SWE), and magnetic resonance elastography (MRE) techniques can be used for staging liver fibrosis as they provide similar diagnostic accuracy. While MRE may be the most accurate, the preferred method should be based on cost and availability.</li> </ol>
SWE liver stiffness measurement threshold recommendations.	<ol style="list-style-type: none"> <li>4. The CAR MASLD WG supports a vendor and modality agnostic 2-step threshold dependent model for risk stratification. The recommended thresholds are as follows: <ol style="list-style-type: none"> <li>5. When FIB-4 score is known and ranges between 1.3 and 2.67: <ol style="list-style-type: none"> <li>a. <math>&lt;8</math> kPa – Low risk for advanced liver disease. Return to routine surveillance with FIB-4 in 1-3 y recommended.</li> <li>b. 8-12 kPa – Indeterminate risk for advanced liver disease. MR elastography, liver biopsy, and/or liver specialist referral may be appropriate.</li> <li>c. <math>&gt;12</math> kPa – Rules in advanced liver disease. Liver specialist referral is recommended.</li> </ol> </li> <li>6. When FIB-4 score is unknown at time of SWE: <ol style="list-style-type: none"> <li>a. <math>&lt;5</math> kPa – Low risk for advanced liver disease. Return to routine surveillance with FIB-4 in 1-3 years recommended in appropriate patients.*</li> <li>b. 5-13 kPa – Indeterminate risk for advanced liver disease. Further testing with FIB-4 is recommended. MR elastography, liver biopsy, and/or liver specialist referral may be appropriate.</li> <li>c. <math>&gt;13</math> kPa – Rules in advanced liver disease. Liver specialist referral is recommended.</li> </ol> </li> <li>7. To date, no known recommendations are risk stratified by modality or vendor, although reproducibility issues between vendors are a recognized limitation. While the benefit of vendor-neutral recommendations is clear, future revisions may necessitate modality and vendor specific thresholds if cross-vendor reproducibility remains a challenge.</li> </ol> </li> </ol>
pSWE and 2D-SWE technical recommendations.	<ol style="list-style-type: none"> <li>8. The CAR MASLD WG supports the SRU recommendations for operator technique which are as follows: <ol style="list-style-type: none"> <li>a. Patient should be fasting for a minimum of 4 h prior to the examination.</li> <li>b. Measurements should be taken in an intercostal space with the patient in supine or slight lateral decubitus (<math>30^\circ</math>) position with right arm in extension.</li> <li>c. Measurement should be taken during breath hold at neutral breathing.</li> <li>d. The 2D SWE region of interest can be positioned closer to the liver capsule, if reverberation artifacts are avoided; however, the measurement box should be positioned at least 15-20 mm below the liver capsule.</li> <li>e. The CAR MASLD WG recommends reporting in kilopascals regardless of modality or vendor. Shear wave speed may be optionally reported as a supplement.</li> <li>f. In most systems, the maximum ARFI push pulse is at 4-4.5 cm from the transducer, which is the optimal location for obtaining measurements.</li> <li>g. In most systems, the ARFI push pulse is attenuated by 6-7 cm, limiting adequate shear wave generation.</li> <li>h. Major potential confounding factors include severe liver inflammation indicated by AST and/or ALT elevation greater than 5 times upper normal limits, obstructive cholestasis, liver congestion, acute hepatitis, and infiltrative liver disease (these all lead to overestimation of the stage of fibrosis).</li> </ol> </li> </ol>

(continued)

Table I. (continued)


Category	Recommendation
	<ul style="list-style-type: none"> <li>i. Ten measurements should be obtained with pSWE, and the final result should be expressed as the median together with the IQR/M.</li> <li>j. Fewer than 10 measurements with pSWE can be obtained (at least 5); however, the IQR/M should be within the recommended range.</li> <li>k. For 2D SWE, 5 measurements should be obtained when the manufacturer's quality criteria are available, and the final result should be expressed as the median together with the IQR/M.</li> <li>l. The most important reliability criterion is an IQR/M of <math>\leq 30\%</math> of the 10 measurements (pSWE) or 5 measurements (2D SWE) for kilopascals and <math>\leq 15\%</math> for measurements in velocity (in meters per second).</li> <li>m. Adequate B-mode liver imaging is a prerequisite for point and 2D SWE as shear waves are tracked with B-mode.</li> </ul>
SWE surveillance threshold recommendations.	9. Follow up studies should be preferentially performed on the same machine with similar technique. The CAR MASLD WG supports the SRU recommendation of 10% delta change for clinically significant variance.
MRE indications.	<p>10. MR elastography should not be the routinely preferred initial liver stiffness measurement modality on account of availability and cost.</p> <p>11. MR elastography may be indicated in the following scenarios:</p> <ul style="list-style-type: none"> <li>a. When FIB-4 score ranges between 1.3 and 2.67 and liver stiffness measurement ranges between 8 and 12 kPa.</li> <li>b. Failed US elastography (such as obese patients and patients with a large volume of ascites).</li> <li>c. Where US elastography techniques are unreliable due to technical issues or show a wide variability (IQR/median <math>\geq 30\%</math>).</li> <li>d. Where US elastography findings are discrepant or contradictory with clinical and laboratory findings.</li> </ul>
MRE magnet strength recommendations.	12. MRE can be performed using either 1.5 or 3 T, depending on availability. 1.5 T may be preferred when both options are available given a lower susceptibility to MR artifacts.
MRE liver stiffness measurement threshold recommendations.	<p>13. When MR elastography is performed for indeterminate risk patients with a FIB-4 score between 1.3 and 2.67 and TE/SWE derived liver stiffness measurement ranges between 8 and 12 kPa:</p> <ul style="list-style-type: none"> <li>a. <math>\leq 3</math> kPa – Low risk for advanced liver disease. Return to routine surveillance with FIB-4 in 1-3 years recommended in appropriate patients.*</li> <li>b. <math>&gt; 3</math> kPa – Advanced liver disease may be present. Liver specialist referral is recommended.</li> </ul> <p>14. When MR elastography is performed for reasons other than indeterminate risk categorization and/or imaging referral is submitted by a liver specialist:</p> <ul style="list-style-type: none"> <li>a. Normal: <math>&lt; 2.5</math> kPa</li> <li>b. Normal or inflammation: <math>\geq 2.5</math>-2.9 kPa</li> <li>c. Stage F1: <math>\geq 3.0</math>-3.5 kPa</li> <li>d. Stage F2: <math>\geq 3.5</math>-4.0 kPa</li> <li>e. Stage F3: <math>\geq 4.0</math>-5.0 kPa</li> <li>f. Stage F4: <math>\geq 5.0</math> kPa</li> </ul>

Note. TE = transient elastography; pSWE = point shear wave elastography; 2D-SWE = 2D shear wave elastography; MRE = magnetic resonance elastography; CAR MASLD WG = Canadian Association of Radiologists Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group; IQR/M = interquartile range/median.

\*Appropriate patients include: (1) 2 or more metabolic risk factors, (2) type 2 diabetes, (3) steatosis on any imaging modality or elevated aminotransferases.

Rationale: In North America, an estimated 30% of the general population have some form of MASLD, with approximately 6% demonstrating features of metabolic dysfunction-associated steatohepatitis (MASH) and 3% of all patients demonstrating features of MASH and significant hepatic fibrosis (F $\geq 2$ ).<sup>6-9</sup> The latter group is deemed to be at-risk for

liver-related events such as liver failure, portal hypertension complications, and/or hepatocellular carcinoma and are known to portend a worse prognosis.<sup>10,11</sup> Non-invasive risk stratification into low and high risk groups for identifying these at-risk patients without liver biopsy has been endorsed by multiple American and European liver societies.<sup>2-4</sup> This



**Figure 1.** CAR MASLD Working Group strategy for population screening and risk stratification of MASLD patients.

Note. Patients who may warrant screening and risk stratification for MASLD include patients with type 2 diabetes mellitus, 2 or more metabolic risk factors (including central obesity, high triglycerides, low HDL cholesterol, hypertension, prediabetes, or insulin resistance), elevated aminotransferases, and/or incidental imaging features suggestive of hepatic steatosis.  $FIB-4 = [Age \text{ (years)} \times AST \text{ (U/L)}] / [Platelet \text{ count } (10^9/L) \times \sqrt{ALT \text{ (U/L)}}]$ . MASLD = metabolic dysfunction-associated steatotic liver disease; TE = vibration controlled transient elastography; SWE = shear wave elastography (may either be point or 2D shear wave elastography); LSM = liver stiffness measurement; MRE = magnetic resonance elastography.

practice satisfies the Canadian disease and test principles for screening programs including epidemiology, natural history, and target population criteria.<sup>12</sup> To further achieve both intervention and system principles necessary for an ethical screening program including program infrastructure, system integration, and cost-effectiveness, an accurate but affordable and widely available pathway for risk stratification is necessary. A 2-step, blood-based followed by imaging-based, non-invasive approach acknowledges the potential for higher-accuracy with imaging-based investigations while also balancing the need for a widely available and cost-effective initial approach.<sup>2-4</sup> The preferential initial use of a blood-based investigation is based on low cost and wide availability.<sup>13</sup>

The supplemental utility of imaging-based investigations in intermediate-risk patients as identified by a blood-based investigation has been suggested to improve the overall accuracy of risk stratification of these patients in differentiating low-risk community surveillance patients and patients requiring additional, potentially more costly or invasive investigations and/or specialist referrals for management.<sup>3</sup> For these reasons, this approach is supported by the CAR MASLD WG for population level screening and referral pathways in primary care. The American Gastroenterological Society recommends screening and risk stratification for MASLD patients with type 2 diabetes mellitus, 2 or more metabolic risk factors (including central obesity, high triglycerides, low HDL

cholesterol, hypertension, prediabetes, or insulin resistance), elevated aminotransferases, and/or incidental imaging features suggestive of hepatic steatosis.<sup>4</sup>

**Recommendation 2: The CAR MASLD WG supports preferential use of FIB-4 investigation as the blood-based investigation of choice. Recommendations are as follows:**

- a. FIB-4 score  $<1.3$  = Low risk for advanced liver disease. Repeat FIB-4 examination in 1-3 years.
- b. FIB-4 score 1.3-2.67 = Indeterminate risk for advanced liver disease. Proceed with imaging-based investigation for liver stiffness measurement.
- c. FIB-4 score  $>2.67$  = High risk for advanced liver disease. Refer to a liver specialist.

Rationale: Direct and indirect blood biomarkers of liver disease lack sufficient accuracy for risk stratifying MASLD patients when used alone.<sup>3,14</sup> Several combination values of blood tests have shown improved accuracy for identifying patients with advanced hepatic fibrosis ( $F \geq 3$ ) including: (1) Fibrosis-4 Index (FIB-4), a calculation using age, AST, ALT, and platelet count; (2) an AST to platelet ratio index (APRI); and (3) an NAFLD fibrosis score (NFS), a calculation using age, BMI, impaired fasting glucose, AST, ALT, and platelet count. Based on a combination of cost, availability, and evidence to date, FIB-4 has since become the most widely recognized calculation for risk stratifying MASLD patients with blood-based investigation.<sup>13,15</sup> FIB-4 demonstrates an area under the receiver operating characteristic curve (AUC) of around 0.7 for detecting MASH and clinically significant fibrosis ( $F \geq 2$ ) and around 0.75 to 0.8 for detecting advanced hepatic fibrosis ( $F \geq 3$ ).<sup>14,16</sup> An original study of 541 patients risk stratified MASLD patients using a low risk threshold of  $<1.3$  with a sensitivity of 74% and negative predictive value (NPV) of 90% and a high risk threshold of  $>2.67$  with a specificity of 98% and positive predictive value of 83% for detecting advanced hepatic fibrosis in patients with MASLD.<sup>17</sup> More recent meta-analyses have approximately supported these performance values with one individual patient data meta-analysis including over 5000 patients identifying a lower FIB-4 threshold of 0.88 for achieving a sensitivity of 90%.<sup>18,19</sup> Based on these findings, multiple recent clinical guidelines have now adopted FIB-4 thresholds of  $<1.3$  to define low risk populations and  $>2.67$  to define high risk populations in MASLD.<sup>2-4</sup> FIB-4 scores between 1.3 and 2.67 represent an indeterminate risk category and warrant further investigation for appropriate risk stratification. Both American and European guidelines have endorsed an imaging-based liver stiffness measurement (LSM) to further risk stratify MASLD patients in this setting to reduce the number of liver biopsies needed.<sup>18</sup> Of note, a recognized limitation of FIB-4 is decreased accuracy at extremes of age and some authors have recommended an age stratified threshold where patients  $\leq 35$  years of age are not

stratified with FIB-4, patients aged 36 to 65 use above noted thresholds, and patients aged  $\geq 65$  use a low risk threshold of 2.0 rather than 1.3.<sup>16</sup> Additionally, alterations of indirect biomarkers underpinning the FIB-4 calculation for reasons other than hepatic fibrosis such as thrombocytopenia, active alcohol use, acute liver inflammation, and chronic renal disease can falsely alter the FIB-4 score.<sup>3</sup> The appropriate use of FIB-4 in these settings should be determined based on approved regional practices by liver specialists.

## Part 2B: Comparative Utility of Modalities for Liver Stiffness Measurement

**Recommendation 3: Transient elastography (TE), point shear wave elastography (pSWE), 2D shear wave elastography (2D-SWE), and magnetic resonance elastography (MRE) techniques can be used for staging liver fibrosis as they provide similar diagnostic accuracy. While MRE may be the most accurate, the preferred method should be based on cost and availability.**

Rationale: Imaging-based investigations for risk stratifying patients with MASLD quantifies the elastic/shear modulus properties of liver parenchyma to generate a Liver Stiffness Measurement (LSM). This LSM serves as a surrogate marker for hepatic fibrosis. The specific techniques for acquisition of a LSM fundamentally differs between each of the modalities with TE and MRE using a form of external mechanical vibrations and SWE using an acoustic vibration known as an acoustic radiation force impulse (ARFI) to generate a single shear wave measurement (pSWE) or a 2-dimensional shear wave image (2D-SWE).<sup>20-23</sup> Further, these techniques are often proprietary to the vendor and may differ between vendors within a single modality such as SWE. Given these fundamentally different techniques and proprietary technologies underpinning the underlying acquisition of each LSM, variable performance may exist between modalities or even between vendors within a single modality. To address this question, the American Association for the Study of Liver Disease (AASLD) recently performed a meta-analysis evaluating the utility of each non-invasive imaging-based modality for detecting and grading hepatic steatosis in over 60,000 adult patients with chronic liver disease across multiple etiologies.<sup>24</sup> Within this analysis of 240 articles, 54 studies evaluated these tools in patients with MASLD. No significant differences in sensitivity between modalities were identified for detecting significant ( $F \geq 2$ ) and advanced ( $F \geq 3$ ) hepatic fibrosis when allowing for some differences in ranges and thresholds by modality (eg, pSWE was reported as velocity [m/s]). MRE appeared to be more specific than the other tools. No head-to-head studies were identified showing clear superiority of one modality. Similar results have been shown in other meta-analyses using different methodologies.<sup>25</sup> As such, multiple societies have now recommended the use of

either TE, SWE, or MRE depending on availability.<sup>2-4</sup> The CAR MASLD WG supports this approach. While MRE may be the most accurate, it is expensive, resource intensive and has limited availability, which likely precludes MRE from routine use as a risk stratification tool at most institutions.

### **Part 2C: SWE Liver Stiffness Measurement Threshold Recommendations**

**Recommendation 4: The CAR MASLD WG supports a vendor and modality agnostic 2-step threshold dependent model for risk stratification.**

Rationale: Current evidence does not show clear superiority of any single image-based investigation for obtaining a LSM. Further, the WG is not aware of any currently available literature showing clear superiority or threshold discrepancies between SWE vendors at the present time. As such, the WG supports both a vendor and modality-agnostic image-based LSM threshold when using TE or SWE for patients deemed to be indeterminate risk on the initial blood-based investigation.

However, while ultrasound-based elastography methods (TE, pSWE, and 2D-SWE) measure shear wave speed (m/s), the accepted practice is to report the computed Young's modulus in kilopascals (kPa), and so our recommendation is to adopt this convention irrespective of modality. Further, while TE and MRE both use external mechanical vibration and provide results in kPa, TE reports the Young's modulus while MRE reports the shear stiffness (understood as the magnitude of the complex shear modulus) and these 2 parameters should not be interpreted on the same scale.

**Recommendation 5: When FIB-4 score is known and ranges between 1.3 and 2.67, recommended SWE thresholds are:**

- a. <8 kPa – Low risk for advanced liver disease. Return to routine surveillance with FIB-4 in 1-3 years recommended.
- b. 8-12 kPa – Indeterminate risk for advanced liver disease. MR elastography, liver biopsy, and/or liver specialist referral may be appropriate.
- c. >12 kPa – Rules in advanced liver disease. Liver specialist referral is recommended.

Rationale: For MASLD patients, multiple American and European societies have endorsed a modality (TE or SWE) and vendor agnostic LSM of <8 kPa in patients with indeterminate risk stratification when using FIB-4 to define a low-risk patient population.<sup>2-4</sup> This is supported by AASLD's recent meta-analysis demonstrating sensitivities of over 80% and likely closer to 90% for both TE and SWE for excluding advanced hepatic fibrosis ( $F \geq 3$ ) in MASLD patients at this threshold.<sup>24</sup> Taken on a large patient population screening

level, a high negative predictive value (>85%) would be achieved at this threshold.<sup>18</sup> By contrast, thresholds with sufficient specificity to warrant a liver specialist referral differ between guidelines, with some recommending referral at the 8 kPa threshold and others defining high risk patients warranting definitive referral above a 12 kPa threshold.<sup>2-4</sup> Given current specialist demands and limited availability in Canada, the CAR MASLD WG supports an indeterminate range of 8 to 12 kPa for which further investigations such as MRE and/or liver biopsy may be appropriate to further assist in risk stratifying these patients. These investigations may be performed in conjunction with and/or following a liver specialist referral, depending on regional practice patterns.

**Recommendation 6: When FIB-4 score is unknown at time of SWE, recommended SWE thresholds are:**

- a. <5 kPa – Low risk for advanced liver disease. Return to routine surveillance with FIB-4 in 1-3 years recommended in appropriate patients.\*
- b. 5-13 kPa – Indeterminate risk for advanced liver disease. Further testing with FIB-4 is recommended. MR elastography, liver biopsy, and/or liver specialist referral may be appropriate.
- c. >13 kPa – Rules in advanced liver disease. Liver specialist referral is recommended.

\*Appropriate patients include: (1) 2 or more metabolic risk factors, (2) type 2 diabetes, (3) steatosis on any imaging modality or elevated aminotransferases.

Rationale: Contrary to recent clinical guidelines noted above, the Society of Radiologists in Ultrasound (SRU) has offered recommendations for risk stratification of MASLD patients using SWE without the pre-existing requirement of a blood-based investigation.<sup>5</sup> As a result, it may be regional practice to offer SWE for some patients without first utilizing a blood-based investigation. In this case, the SRU has adopted a conservative "rule of four" guideline in which a 5 kPa threshold "rules out" disease while a 13 kPa threshold "rules in" disease. The SRU further risk stratifies patients as unlikely to have advanced hepatic fibrosis without other known clinical signs (5-<9 kPa) and suggestive of advanced hepatic fibrosis but requiring further testing confirmation (9-13 kPa). However, they explicitly recognize that MASLD patients may have lower thresholds for advanced hepatic fibrosis and also suggest further testing in some patients with thresholds between 7 and 9 kPa. These values are somewhat supported by results of AASLD's recent meta-analysis.<sup>24</sup> As a measure of precaution and recognizing that some variability likely exists between vendors and SWE modalities (pSWE vs 2D-SWE), the CAR MASLD WG supports a more broadly encompassing indeterminate range for which further investigation with both FIB-4 and possibly additional investigations (such as MRE and/or liver biopsy) and/or liver specialist referral may be appropriate, determined on an individualized basis and regional practice patterns.

**Recommendation 7:** *To date, no known recommendations are risk stratified by modality or vendor, although reproducibility issues between vendors are a recognized limitation. While the benefit of vendor-neutral recommendations is clear, future revisions may necessitate modality and vendor specific thresholds if cross-vendor reproducibility remains a challenge.*

Rationale: As detailed in Recommendation #3, physical principles for LSM acquisition differ fundamentally between modalities. Further, unlike TE, which is a single-vendor product in North America, technical implementations of pSWE and 2D-SWE differ between vendors. MRE uses a standardized commercially available product across all major vendors. As such, it is possible that important differences between and within modalities are not clearly defined in the literature. The CAR MASLD WG recognizes the practical utility of a single unified threshold-based recommendation and endorses recent guidelines that have done the same. However, we also recognize the evolving nature of the SWE and MRE literature, and as adoption broadens, we acknowledge that modality and/or vendor specific recommendations may be necessary with future revisions of these guidelines.

#### Part 2D: pSWE and 2D-SWE Technical Recommendations

**Recommendation 8:** *The CAR MASLD WG supports the SRU recommendations for operator technique which are as follows:*

- a. Patient should be fasting for a minimum of 4h prior to the examination.
- b. Measurements should be taken in an intercostal space with the patient in supine or slight lateral decubitus (30°) position with right arm in extension.
- c. Measurement should be taken during breath hold at neutral breathing.
- d. The 2D SWE region of interest can be positioned closer to the liver capsule, if reverberation artifacts are avoided; however, the measurement box should be positioned at least 15-20mm below the liver capsule.
- e. The CAR MASLD WG recommends reporting in kilopascals regardless of modality or vendor. Shear wave speed may be optionally reported as a supplement.
- f. In most systems, the maximum ARFI push pulse is at 4-4.5 cm from the transducer, which is the optimal location for obtaining measurements.
- g. In most systems, the ARFI push pulse is attenuated by 6-7 cm, limiting adequate shear wave generation.
- h. Major potential confounding factors include severe liver inflammation indicated by AST and/or ALT elevation greater than 5 times upper normal limits, obstructive cholestasis, liver congestion, acute hepatitis, and infiltrative liver disease (these all lead to overestimation of the stage of fibrosis).

- i. Ten measurements should be obtained with pSWE, and the final result should be expressed as the median together with the IQR/M.
- j. Fewer than 10 measurements with pSWE can be obtained (at least 5); however, the IQR/M should be within the recommended range.
- k. For 2D SWE, 5 measurements should be obtained when the manufacturer's quality criteria are available, and the final result should be expressed as the median together with the IQR/M.
- l. The most important reliability criterion is an IQR/M of  $\leq 30\%$  of the 10 measurements (pSWE) or 5 measurements (2D SWE) for kilopascals and  $\leq 15\%$  for measurements in velocity (in meters per second).
- m. Adequate B-mode liver imaging is a prerequisite for point and 2D SWE as shear waves are tracked with B-mode.

Rationale: The reliability of SWE LSM is highly dependent on operator technique. To unify and standardize acquisitions across practices and technicians, the SRU has adopted similar standards to those recommended by the European Federation of Societies for Ultrasound in Medicine and Biology and the World Federation for Ultrasound in Medicine and Biology.<sup>5</sup> The CAR MASLD WG also endorses these technical recommendations but further suggests preferential unified reporting in kPa across modalities, including with pSWE which has traditionally reported in velocity rather than Young's Modulus. Shear wave speed may be optionally reported as a supplement. Specific attention should be made to potential confounders of elevated LSM including recent postprandial status and other causes of liver inflammation noted in Recommendation 8h.

The CAR MASLD WG also recognizes that recent literature has proposed the evaluation of SWE LSM reliability on an individualized measurement basis, and this approach has been endorsed by the French Hepatology and Abdominal Radiology Societies.<sup>26,27</sup> The WG consensus is that this technique remains investigational at the present time and may be cumbersome in clinical practice, requiring a conversion chart for the coefficient of variation.<sup>26</sup> We currently support the SRU recommendation for a combined IQR/median of  $\leq 30\%$  as the reliability measure of choice (recommendation 8i).

#### Part 2E: SWE Surveillance Threshold Recommendations

**Recommendation 9:** *Follow up studies should be preferentially performed on the same machine with similar technique. The CAR MASLD WG supports the SRU recommendation of 10% delta change for clinically significant variance.*

Rationale: Given potential variability between vendors and modalities described in recommendations 3 and 7 and even potential variability between machines, the CAR MASLD WG supports SRU recommendations for using the same machines to reduce the risk of technical variability for the same patient on follow-up, when possible. We further support the SRU suggested delta change  $\geq 10\%$  as being clinically significant to account for variability that may occur within and/or between vendors for SWE.<sup>5,28</sup>

## Part 2F: MRE Indications

**Recommendation 10: MR elastography should not be the routinely preferred initial liver stiffness measurement modality on account of availability and cost.**

Rationale: While MRE may be the most accurate modality for LSM, MRE availability, resource demands and cost, limit its use as the first-line elastographic technique for screening at the population level screening. The WG agrees that this should not be the routinely preferred modality for image-based investigation in Canada.

**Recommendation 11: MR elastography may be indicated in the following scenarios:**

- When FIB-4 score ranges between 1.3 and 2.67 and liver stiffness measurement ranges between 8 and 12 kPa.
- Failed US elastography (such as obese patients and patients with a large volume of ascites).
- Where US elastography techniques are unreliable due to technical issues or show a wide variability (IQR/median  $\geq 30\%$ ).
- Where US elastography findings are discrepant or contradictory with clinical and laboratory findings.

Rationale: MRE has been validated against histopathology and has shown higher overall diagnostic accuracy compared to TE and SWE in MASLD patients based on multiple meta-analyses.<sup>3,24</sup> Meta-analyses by Singh et al and Su et al investigated the accuracy of MRE in grading liver fibrosis using histopathology as the reference standard. Singh et al (697 patients from 12 studies) found AUCs of 0.88 (95% CI, 0.84-0.91) for  $F \geq 2$ , 0.93 (95% CI, 0.90-0.95) for  $F \geq 3$ , and 0.92 (95% CI, 0.90-0.94) for  $F = 4$ .<sup>29</sup> Su et al (989 patients from 13 studies) found AUCs of 0.97 for  $F \geq 2$ , 0.96 for  $F \geq 3$ , and 0.98 for  $F = 4$ .<sup>30</sup> A systematic review and pooled analysis comparing MRE with transient elastography (TE) in 230 patients with MASLD found that MRE had superior accuracy to TE in determining fibrosis grade. AUCs for MRE versus TE were: 0.92 (95% CI, 0.88-0.96) versus 0.87 (95% CI, 0.82-0.91) for  $F \geq 2$  ( $P = .03$ ), 0.93 (95% CI, 0.89-0.96) versus 0.84 (95% CI, 0.78-0.90) for  $F \geq 3$  ( $P = .001$ ), and 0.94 (95% CI, 0.89-0.96) versus 0.84 (95% CI, 0.73-0.94) for  $F 4$  ( $P = .005$ ).<sup>31</sup>

Unlike ultrasound elastography techniques and liver biopsy, which can only sample small regions of the liver, and liver biopsy, which has inherent risks of an invasive procedure, MRE serves as a non-invasive tool which can evaluate a substantially larger liver volume. This allows MRE to estimate whole liver disease burden more accurately, a noteworthy consideration as fibrosis often affects the liver heterogeneously. As such, MRE is a preferred tool for risk stratifying patients with MASLD, particularly when other more accessible and cost-effective modalities fail or remain indeterminate. Additionally, MRE serves an increasingly important role in enabling longitudinal patient monitoring and treatment response evaluation and is a desirable tool for use in clinical trials.

Nevertheless, ultrasound elastography techniques remain more readily available and cost-effective than MRE, making TE and SWE more practical screening tools in large patient populations such as MASLD. As an adjunct to TE and SWE, MRE can serve a supplementary role in the scenarios detailed in recommendation #11.

## Part 2G: MR Magnet Strength Recommendations

**Recommendation 12: MRE can be performed using either 1.5 or 3 T, depending on availability. 1.5 T may be preferred when both options are available given a lower susceptibility to MR artifacts.**

Rationale: MRE can be performed on both 1.5 and 3 T MR systems, the choice of which depends on local availability and resources. Due to higher gradient strength, 3 T MR systems are more susceptible to MR artifacts than 1.5 T systems. A study of 781 MRE examinations found a higher technical failure rate on 3 T (15.3%) compared to 1.5 T (3.5%) with the main causes of failure being iron deposition, high body mass index, and massive ascites.<sup>32</sup>

## Part 2H: MRE Liver Stiffness Threshold Recommendations

**Recommendation 13: When MR elastography is performed for indeterminate risk patients with a FIB-4 score between 1.3 and 2.67 and TE/SWE derived liver stiffness measurement ranges between 8 and 12 kPa:**

- $\leq 3$  kPa – Low risk for advanced liver disease. Return to routine surveillance with FIB-4 in 1-3 years recommended in appropriate patients.
- $> 3$  kPa – Advanced liver disease may be present. Liver specialist referral is recommended.

Rationale: A 2021 meta-analysis of LSMs in MASLD patients performed by the LITMUS investigators included 11 studies evaluating MRE.<sup>33</sup> Thresholds ranging from 2.86 to 4.14 identified significant hepatic fibrosis ( $F \geq 2$ ) with a sensitivity of

78%, specificity of 89% and AUC of 0.91 while thresholds of 2.99 to 4.80 identified advanced hepatic fibrosis ( $F \geq 3$ ) with a sensitivity of 83%, specificity of 89% and AUC of 0.92. By contrast, a 2024 meta-analysis performed by AASLD used thresholds between 3.2 and 3.6 kPa for identifying significant hepatic fibrosis with a sensitivity of 78% and specificity of 90% and thresholds of 3.6 to 3.9 kPa for detecting advanced hepatic fibrosis with a sensitivity of 82% to 93% and specificity of 90% to 95%.<sup>24</sup> Using these results, the AASLD has endorsed a MRE-LSM  $<3.1$  kPa in MASLD patients with a FIB-4 score  $>1.3$  to 2.67 as warranting further surveillance or possible biopsy.<sup>3</sup> A recent multi-society European guideline has also suggested surveillance in appropriate patients without advanced hepatic fibrosis in appropriate patients, with a referenced MRE-LSM threshold of 3.53 kPa in their guidelines.<sup>2</sup> For simplicity, we recommend a threshold of  $\leq 3$  kPa as warranting low risk stratification in patients with intermediate risk blood-based and US image-based scoring.

**Recommendation 14: When MR elastography is performed for reasons other than indeterminate risk categorization and/or imaging referral is submitted by a liver specialist:**

- a. Normal:  $<2.5$  kPa
- b. Normal or inflammation:  $\geq 2.5$ - $2.9$  kPa
- c. Stage F1:  $\geq 3.0$ - $3.5$  kPa
- d. Stage F2:  $\geq 3.5$ - $4.0$  kPa
- e. Stage F3:  $\geq 4.0$ - $5.0$  kPa
- f. Stage F4:  $\geq 5.0$  kPa

Rationale: When performed outside of a risk stratification pathway, the CAR MASLD WG supports thresholds originally established by the Mayo Clinic and subsequently endorsed by the members of the Society of Abdominal Radiologists (SAR) Liver Fibrosis Disease-Focused Panel (DFP) and European Society of Radiology.<sup>34-39</sup> These are independent of magnet strength, pulse sequences, or vendor platform. These values would align with meta-analyses indicating a high probability of being normal when  $<2.5$  kPa and high probability of being abnormal when  $>5$  kPa.<sup>24,33</sup> We recognize that individualized defined thresholds endorsed in this approach between 3-5 kPa may lack nuance for potential threshold variability and disease severity overlap identified between studies in more recent pooled analyses outlined above.

Like other LSM modalities, other causes of increased liver stiffness including recent post-prandial status, hepatic inflammation, biliary obstruction, hepatic congestion, focal liver masses, and infiltrative liver processes should be recognized and avoided when possible. As such, it is important that MRE-LSMs are interpreted together with the clinical and laboratory data and risk stratification be determined on an individualized basis. Required fasting for 4 to 6 hours is also necessary before MRE examinations.

## Conclusion

Part 2 of the CAR MASLD WG guidelines outlines 14 recommendations for best practice risk stratification of MASLD patients into low and high risk for advanced hepatic fibrosis using the FIB-4 score and image-based investigations. Indications, grading, and technical recommendations for performing SWE and MRE are provided based on existing literature. The CAR MASLD WG recognizes that the literature is rapidly evolving in this field as patient population risk stratification becomes more widely adopted. We anticipate periodic updates of these recommendations over the next 3 to 5-years. In addition to detecting and grading hepatic steatosis (Part 1) and risk stratifying MASLD patients (Part 2), Part 3 of the CAR MASLD WG recommendations will offer guidance for SWE and MRE program implementation and quality assurance.<sup>40</sup>


## Abbreviations

AASLD	American Association for the Study of Liver Disease
ALT	aminotransferase level
APRI	AST to platelet ratio index
AST	aspartate aminotransferase level
AUC	area under the receiver operating characteristic curve
CAR	Canadian Association of Radiologists
CLD	chronic liver disease
CSAR	Canadian Society of Abdominal Radiologists
CT	computed tomography
FIB-4	Fibrosis-4 Index
HCC	hepatocellular carcinoma
HRI	hepatorenal index
HU	Hounsfield units
HVPG	hepatic venous pressure gradient
IP	in-phase
LSM	liver stiffness measurement
MASH	metabolic dysfunction-associated steatohepatitis
MASLD	metabolic dysfunction-associated steatotic liver disease
MRE	magnetic resonance elastography
MRI	magnetic resonance imaging
MRS	magnetic resonance spectroscopy
NAFLD	nonalcoholic fatty liver disease
NIMBLE	Non-invasive Biomarkers of Metabolic Liver Disease
NPV	negative predictive value
OP	out-of-phase
PDFF	proton density fat fraction
pSWE	point shear wave elastography
PVT	portal vein thrombosis
QUS	quantitative ultrasound
SAR DFP	Society of Abdominal Radiology Disease-Focused Panel
SRU	Society of Radiologists in Ultrasound
SWE	shear wave elastography

TE	transient elastography
US	ultrasound
WFUMB	World Federation for Ultrasound in Medicine and Biology
WG	working group

### ORCID iDs

Mitchell P. Wilson  <https://orcid.org/0000-0002-1630-5138>

Gavin Low  <https://orcid.org/0000-0002-4959-8934>

Andreu F. Costa  <https://orcid.org/0000-0003-1683-8230>

An Tang  <https://orcid.org/0000-0001-8967-5503>

Silvia Chang  <https://orcid.org/0000-0002-9201-8114>

Alexandra Medellin  <https://orcid.org/0000-0003-3177-5266>


Jérémy Dana  <https://orcid.org/0000-0003-0352-4128>

Ania Kielar  <https://orcid.org/0000-0001-6887-5266>

Li Xin Zhang  <https://orcid.org/0000-0002-1073-103X>

Daisy Fung  <https://orcid.org/0009-0001-8101-3588>

Casey Hurrell  <https://orcid.org/0000-0003-0453-2576>

Christopher Fung  <https://orcid.org/0000-0001-7516-8631>

### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### References

- Wilson MP, Tang A, Low G, et al. Part 1: CAR metabolic dysfunction-associated steatotic liver disease working group guidance statements for detecting and grading hepatic steatosis using ultrasound, CT, or MRI. *Can Assoc Radiol J*. Published online 2025. doi:10.1177/08465371251357444
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol*. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031
- Sterling RK, Duarte-Rojo A, Patel K, et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. *Hepatology*. 2025;81(2):672-724. doi:10.1097/HEP.0000000000000843
- Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2021;161(5):1657-1669. doi:10.1053/j.gastro.2021.07.049
- Barr RG, Wilson SR, Rubens D, Garcia-Tsao G, Ferraioli G. Update to the Society of Radiologists in Ultrasound Liver Elastography consensus statement. *Radiology*. 2020;296(2):263-274. doi:10.1148/radiol.2020192437
- Hosseini Shabanan S, Martins VF, Wolfson T, et al. MASLD: what we have learned and where we need to go—a call to action. *Radiographics*. 2024;44(11):e240048. doi:10.1148/rg.240048
- Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2022;7(9):851-861. doi:10.1016/S2468-1253(22)00165-0
- Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology*. 2023;77(4):1335-1347. doi:10.1097/HEP.0000000000000004
- Payne JY, Alkhoury N, Le P, et al. Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017-2018. *Hepatol Commun*. 2023;7(1):e0019. doi:10.1097/HC9.0000000000000019
- Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2015;149(2):389-397.e10. doi:10.1053/j.gastro.2015.04.043
- Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. *J Hepatol*. 2017;67(6):1265-1273. doi:10.1016/j.jhep.2017.07.027
- Dobrow MJ, Hagens V, Chafe R, Sullivan T, Rabeneck L. Consolidated principles for screening based on a systematic review and consensus process. *CMAJ*. 2018;190(14):E422-E429. doi:10.1503/cmaj.171154
- Congly SE, Shaheen AA, Swain MG. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. *PLOS ONE*. 2021;16(5):e0251741. doi:10.1371/journal.pone.0251741
- Vali Y, Lee J, Boursier J, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. *Lancet Gastroenterol Hepatol*. 2023;8(8):714-725. doi:10.1016/S2468-1253(23)00017-1
- Abeysekera KWM, Valenti L, Younossi Z, et al. Implementation of a liver health check in people with type 2 diabetes. *Lancet Gastroenterol Hepatol*. 2024;9(1):83-91. doi:10.1016/S2468-1253(23)00270-4
- McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. *Am J Gastroenterol*. 2017;112(5):740-751. doi:10.1038/ajg.2016.453
- Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol*. 2009;7(10):1104-1112. doi:10.1016/j.cgh.2009.05.033
- Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut*. 2022;71(5):1006-1019. doi:10.1136/gutjnl-2021-324243
- Han JW, Kim HY, Yu JH, et al. Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis. *Clin Mol Hepatol*. 2024;30(Suppl):S147-S158. doi:10.3350/cmh.2024.0330

20. Mueller S, Sandrin L. Liver stiffness: a novel parameter for the diagnosis of liver disease. *Hepatic Med Evid Res*. 2010;2:49-67. doi:10.2147/hmer.s7394
21. Ozturk A, Grajo JR, Dhyani M, Anthony BW, Samir AE. Principles of ultrasound elastography. *Abdom Radiol (NY)*. 2018;43(4):773-785. doi:10.1007/s00261-018-1475-6
22. Taljanovic MS, Gimber LH, Becker GW, et al. Shear-wave elastography: basic physics and musculoskeletal applications. *Radiographics*. 2017;37(3):855-870. doi:10.1148/rg.2017160116
23. Low G, Kruse SA, Lomas DJ. General review of magnetic resonance elastography. *World J Radiol*. 2016;8(1):59-72. doi:10.4329/wjr.v8.i1.59
24. Duarte-Rojo A, Taouli B, Leung DH, et al. Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline. *Hepatology*. 2025;81(2):725-748. doi:10.1097/HEP.0000000000000852
25. Yamaguchi R, Oda T, Nagashima K. Comparison of the diagnostic accuracy of shear wave elastography with transient elastography in adult nonalcoholic fatty liver disease: a systematic review and network meta-analysis of diagnostic test accuracy. *Abdom Radiol (NY)*. 2025;50(2):734-746. doi:10.1007/s00261-024-04546-8
26. Paisant A, Lemoine S, Cassinotto C, et al. Reliability criteria of two-dimensional shear wave elastography: analysis of 4277 measurements in 788 patients. *Clin Gastroenterol Hepatol*. 2022;20(2):400-408.e10. doi:10.1016/j.cgh.2020.12.013
27. Parlati L, Aubé C, Lewin M, Boursier J, Ronot M, Paisant A. Réalisation de l'élastographie ultrasonore en pratique clinique: Avid des experts de l'AFEF et de la SIAD. Published online October 2024. Accessed February 3, 2025. [https://afef.asso.fr/wp-content/uploads/2024/11/AFEF\\_2410\\_4316-Avis-experts-elasto-echo-3.pdf](https://afef.asso.fr/wp-content/uploads/2024/11/AFEF_2410_4316-Avis-experts-elasto-echo-3.pdf)
28. Palmeri ML, Milkowski A, Barr R, et al. Radiological Society of North America/quantitative imaging biomarker alliance shear wave speed bias quantification in elastic and viscoelastic phantoms. *J Ultrasound Med*. 2021;40(3):569-581. doi:10.1002/jum.15609
29. Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. *Clin Gastroenterol Hepatol*. 2015;13(3):440-451.e6. doi:10.1016/j.cgh.2014.09.046
30. Su LN, Guo SL, Li BX, Yang P. Diagnostic value of magnetic resonance elastography for detecting and staging of hepatic fibrosis: a meta-analysis. *Clin Radiol*. 2014;69(12):e545-e552. doi:10.1016/j.crad.2014.09.001
31. Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. *Clin Gastroenterol Hepatol*. 2019;17(4):630-637.e8. doi:10.1016/j.cgh.2018.05.059
32. Wagner M, Corcuera-Solano I, Lo G, et al. Technical failure of MR elastography examinations of the liver: experience from a large single-center study. *Radiology*. 2017;284(2):401-412. doi:10.1148/radiol.2016160863
33. Selvaraj EA, Mozes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. *J Hepatol*. 2021;75(4):770-785. doi:10.1016/j.jhep.2021.04.044
34. Guglielmo FF, Barr RG, Yokoo T, et al. Liver fibrosis, fat, and iron evaluation with MRI and fibrosis and fat evaluation with US: a practical guide for radiologists. *Radiographics*. 2023;43(6):e220181. doi:10.1148/rg.220181
35. Venkatesh SK, Ehman RL. Magnetic resonance elastography of liver. *Magn Reson Imaging Clin N Am*. 2014;22(3):433-446. doi:10.1016/j.mric.2014.05.001
36. Srinivasa Babu A, Wells ML, Teytelboym OM, et al. Elastography in chronic liver disease: modalities, techniques, limitations, and future directions. *Radiographics*. 2016;36(7):1987-2006. doi:10.1148/rg.2016160042
37. Ozturk A, Kumar V, Pierce TT, et al. The future is beyond bright: the evolving role of quantitative US for fatty liver disease. *Radiology*. 2023;309(2):e223146. doi:10.1148/radiol.223146
38. Hu HH, Yokoo T, Bashir MR, et al. Linearity and bias of proton density fat fraction as a quantitative imaging biomarker: a multicenter, multiplatform, multivendor phantom study. *Radiology*. 2021;298(3):640-651. doi:10.1148/radiol.2021202912
39. Moura Cunha G, Fan B, Navin PJ, et al. Interpretation, reporting, and clinical applications of liver MR elastography. *Radiology*. 2024;310(3):e231220. doi:10.1148/radiol.231220
40. Wilson MP, Low G, Medellin A, et al. Part 3: CAR dysfunction-associated steatotic liver disease working group recommendations for ultrasound shear wave elastography and MR elastography program implementation, funding, and quality assurance. *Can Assoc Radiol J*. Published online 2025. doi:10.1177/08465371251357446